FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W89455151> ?p ?o ?g. }

• W89455151 abstract "Abstract Background Bortezomib-based combinations, including alkylating agents (VMP or CyBorD) or immunomodulatory drugs (VTD or RVD) have been established as regimens widely used in newly diagnosed MM patients. Bendamustine is a bifunctional alkylating agent effective in relapsed and/or refractory MM patients, and approved in Europe in combination with prednisone for elderly newly diagnosed MM. Since bendamustine may be more efficient than other alkylators, an attractive possibility would be to explore it in combination with bortezomib and prednisone (BVP) in newly diagnosed MM patients both transplant and non transplant candidates. Patients and Methods 60 newly diagnosed MM patients were included in the trial. The first cycle consisted on bendamustine at 90 mg/m2 given IV on days 1 and 4, in combination with bortezomib at 1,3 mg/m2 given IV on days 1, 4, 8, 11, 22, 25, 29 and 32 and prednisone at 60 mg/m2 given PO on days 1 to 4. In the following cycles, bendamustine was given on days 1 and 8, and bortezomib on days 1, 8, 15 and 22 (weekly schedule), and prednisone as it was previously described. Patients younger than 65 years proceeded to peripheral blood stem cell collection (PBSC) using growth factors alone after 4 cycles; HDT-ASCT was performed after 6 cycles. Patients older than 65 years received up to nine 28-day cycles. Results Between May 2011 and July 2012 enrollment was completed (60 pts). Median age was 61 years (range 38-82; 18 pts ≥65), 67% had ISS stage II/III, and 67% had unfavorable cytogenetics: t(4;14), t(14;16), del 17p or 1q gains by FISH. After a median of 6 cycles (2-9), 75% of patients achieved at least PR, including 16% of sCR, 9% CR and 28% of VGPR. Although the differences were not statistically significant, there was a trend to higher CR rate in the group of patients <65 years (31%) compared with elderly patients (11%). No differences were observed in overall response rates and CR rates in patients with standard and high risk cytogenetic abnormalities. Forty patients proceeded to stem cell collection after a median of 4 cycles of BVP. Upon using G-CSF alone, 14 pts (35%) failed to collect a minimun of 2 x 106 CD34+ cells/Kg. An ammendment was done and plerixafor was recomended for poor mobilizers (peripheral CD34 cell count inferior to 10/μL on day 4); all patients but 2 achieved, with G-CSF plus plerixafor, the minimum of CD34+ cells required to proceed to ASCT. These 2 patients successfully collected CD34+ cells using chemotherapy plus G-CSF and plerixafor. Of the 31 patients who received HDT-ASCT, sCR and CR rate before transplant was 18% and 13%, respectively, upgrading up to 39% of sCR and 13% CR after transplant. 7 pts (22%) achieved immunophenotypic CR. After a median f/u of 12 months (5-25), 8 pts have progressed, resulting in a 15-m TTP of 85%. Concerning OS, 89% of patients remained alive at 15 months. None of patients achieving sCR and CR have progressed and all of them are alive at 15 months. Regarding cytogenetic abnormalities, although there were not significant differences, one patient progressed in standard risk group and five in the high risk subgroup resulting in a 15 m-TTP of 93% vs 85%. No significant differences have been observed in terms of 15 m-OS between standard and high risk cytogenetic subgroup (100% vs 92%, respectively). As far as toxicity is concerned, hematologic toxicities included: G3/4 anemia (11%), neutropenia (23%), and thrombocytopenia (14%). The most common G3/4 non-hematologic toxicities were: asthenia (10%), infections (9%), and peripheral neuropathy (4%). Conclusions In patients candidates to HDT-ASCT, response rates obtained before and after transplant are comparable to other three drug bortezomib-based combinations, such as VTD or CyBorD. However, growth factors alone for stem cell collection after four BVP cycles as induction resulted in a 35% of poor mobilizers who were rescued with plerixafor. In the elderly population, although the number of patients included was small, BVP seems not superior to VMP in response rates. Disclosures: Mateos: Janssen, Mundipharma: Honoraria. Off Label Use: bendamustine plus bortezomib and prednisone is not an approved combination for first line of therapy. Oriol:Celgene: Consultancy. Ocio:Onyx: Consultancy, Research Funding; Novartis: Consultancy; Array Biopharma: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy; Celgene: Consultancy, Research Funding. Alegre:Celgene: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity’s Board of Directors or advisory committees, Research Funding. Bladé:Janssen, Mundipharma: Honoraria. San Miguel:Janssen, Mundipharma: Membership on an entity’s Board of Directors or advisory committees." @default.
• W89455151 created "2016-06-24" @default.
• W89455151 creator A5005731938 @default.
• W89455151 creator A5008759843 @default.
• W89455151 creator A5013568680 @default.
• W89455151 creator A5015898454 @default.
• W89455151 creator A5016479494 @default.
• W89455151 creator A5020420490 @default.
• W89455151 creator A5029159537 @default.
• W89455151 creator A5029238392 @default.
• W89455151 creator A5029958963 @default.
• W89455151 creator A5031837957 @default.
• W89455151 creator A5032722606 @default.
• W89455151 creator A5034182883 @default.
• W89455151 creator A5034430204 @default.
• W89455151 creator A5050897050 @default.
• W89455151 creator A5054952877 @default.
• W89455151 creator A5056460838 @default.
• W89455151 creator A5057553435 @default.
• W89455151 creator A5057834186 @default.
• W89455151 creator A5059428070 @default.
• W89455151 creator A5071261900 @default.
• W89455151 date "2013-11-15" @default.
• W89455151 modified "2023-10-18" @default.
• W89455151 title "Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM)" @default.
• W89455151 doi "https://doi.org/10.1182/blood.v122.21.2155.2155" @default.
• W89455151 hasPublicationYear "2013" @default.
• W89455151 type Work @default.
• W89455151 sameAs 89455151 @default.
• W89455151 citedByCount "3" @default.
• W89455151 countsByYear W894551512014 @default.
• W89455151 countsByYear W894551512015 @default.
• W89455151 crossrefType "journal-article" @default.
• W89455151 hasAuthorship W89455151A5005731938 @default.
• W89455151 hasAuthorship W89455151A5008759843 @default.
• W89455151 hasAuthorship W89455151A5013568680 @default.
• W89455151 hasAuthorship W89455151A5015898454 @default.
• W89455151 hasAuthorship W89455151A5016479494 @default.
• W89455151 hasAuthorship W89455151A5020420490 @default.
• W89455151 hasAuthorship W89455151A5029159537 @default.
• W89455151 hasAuthorship W89455151A5029238392 @default.
• W89455151 hasAuthorship W89455151A5029958963 @default.
• W89455151 hasAuthorship W89455151A5031837957 @default.
• W89455151 hasAuthorship W89455151A5032722606 @default.
• W89455151 hasAuthorship W89455151A5034182883 @default.
• W89455151 hasAuthorship W89455151A5034430204 @default.
• W89455151 hasAuthorship W89455151A5050897050 @default.
• W89455151 hasAuthorship W89455151A5054952877 @default.
• W89455151 hasAuthorship W89455151A5056460838 @default.
• W89455151 hasAuthorship W89455151A5057553435 @default.
• W89455151 hasAuthorship W89455151A5057834186 @default.
• W89455151 hasAuthorship W89455151A5059428070 @default.
• W89455151 hasAuthorship W89455151A5071261900 @default.
• W89455151 hasConcept C126322002 @default.
• W89455151 hasConcept C141071460 @default.
• W89455151 hasConcept C2776063141 @default.
• W89455151 hasConcept C2776364478 @default.
• W89455151 hasConcept C2777478702 @default.
• W89455151 hasConcept C2778684742 @default.
• W89455151 hasConcept C2778720950 @default.
• W89455151 hasConcept C2779338263 @default.
• W89455151 hasConcept C2780653079 @default.
• W89455151 hasConcept C2781442060 @default.
• W89455151 hasConcept C71924100 @default.
• W89455151 hasConcept C90924648 @default.
• W89455151 hasConceptScore W89455151C126322002 @default.
• W89455151 hasConceptScore W89455151C141071460 @default.
• W89455151 hasConceptScore W89455151C2776063141 @default.
• W89455151 hasConceptScore W89455151C2776364478 @default.
• W89455151 hasConceptScore W89455151C2777478702 @default.
• W89455151 hasConceptScore W89455151C2778684742 @default.
• W89455151 hasConceptScore W89455151C2778720950 @default.
• W89455151 hasConceptScore W89455151C2779338263 @default.
• W89455151 hasConceptScore W89455151C2780653079 @default.
• W89455151 hasConceptScore W89455151C2781442060 @default.
• W89455151 hasConceptScore W89455151C71924100 @default.
• W89455151 hasConceptScore W89455151C90924648 @default.
• W89455151 hasLocation W894551511 @default.
• W89455151 hasOpenAccess W89455151 @default.
• W89455151 hasPrimaryLocation W894551511 @default.
• W89455151 hasRelatedWork W2208304134 @default.
• W89455151 hasRelatedWork W2471307268 @default.
• W89455151 hasRelatedWork W2513671328 @default.
• W89455151 hasRelatedWork W2526005201 @default.
• W89455151 hasRelatedWork W2541589427 @default.
• W89455151 hasRelatedWork W2550148010 @default.
• W89455151 hasRelatedWork W2554370865 @default.
• W89455151 hasRelatedWork W2555090704 @default.
• W89455151 hasRelatedWork W2557693560 @default.
• W89455151 hasRelatedWork W2563287095 @default.
• W89455151 hasRelatedWork W2565604933 @default.
• W89455151 hasRelatedWork W2566742544 @default.
• W89455151 hasRelatedWork W2567624910 @default.
• W89455151 hasRelatedWork W2572116053 @default.
• W89455151 hasRelatedWork W2580547579 @default.
• W89455151 hasRelatedWork W2588282992 @default.
• W89455151 hasRelatedWork W2588670641 @default.
• W89455151 hasRelatedWork W2590058813 @default.
• W89455151 hasRelatedWork W2603559299 @default.
• W89455151 hasRelatedWork W3023340596 @default.

• next